[PDF] Top 20 Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes

... diabetes-related coronary disease include inflammation and a prothrombotic state. In the setting of non-ST-segment elevation acute coronary syndromes ... Voir le document complet

... for patients randomized to placebo that have baseline MBL ...ratios with 95% confidence intervals and the Score test statistic and associated P-value are ... Voir le document complet

... Primary percutaneous coronary intervention was performed accord- ing to the international ...guidelines. Patients were on dual antiplatelet therapy at the time of the procedure, usually loaded ... Voir le document complet

... 1397) in the triage of low- to intermediate-risk pa- tients presenting with acute chest pain to emergency departments without signs of ischaemia on ECG and/or inconclusive cardiac tro- ...outcomes ... Voir le document complet

... 7243 patients with NSTE- ACS ,75 years of age selected for medical management to clopido- grel or prasugrel for a median duration of 17 ...associated with a statistically significant reduc- tion ... Voir le document complet

... Chew, Baris Gencer, Gerd Hasenfuss, Keld Kjeldsen, Patrizio Lancellotti, Ulf Landmesser, Julinda Mehilli, Debabrata Mukherjee, Robert F. Storey, and Stephan Windecker Article[r] ... Voir le document complet

... and coronary thrombi Laboratory parameters were measured using standard ...30 coronary thrombi were aspirated using an Export catheter (Medtronic, Tolochenaz, Switzerland) at the site of coronary ... Voir le document complet

... Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the ... Voir le document complet

... of non-ST-segment elevation ACS is widely accepted, based on large clinical ...data. In this class of antithrom- botic agents costs remains a major ...reduced with the addition ... Voir le document complet

... shown in the Appendix in the online-only Data Supplement ...indicates acute coronary syndrome; ARCTIC, bedside monitoring to adjust antiplatelet therapy for coronary stenting; BARC, ... Voir le document complet

... includes ST-segment–elevation myocardial infarction (STEMI) and non –ST-segment–elevation ACS (NSTE-ACS) which included non ... Voir le document complet

... target coronary artery was performed and transferred to the Montreal Heart Institute core IVUS laboratory for a quality ...target coronary artery in which IVUS was performed at baseline needed to ... Voir le document complet

... gaps in the current scientific knowledge: 1. There remains uncertainty in terms of whether the superiority in mortality reduction with primary percutaneous coronary ... Voir le document complet

... PCI, in patients with or without indication for chronic ...studies), non-English-language studies, editorial, letters, expert opinions, case reports or series and studies with ... Voir le document complet

... 2011 Diabetic mellitus (DM) patients with coronary artery disease (CAD) are at higher risk of cardiovascular events compared with non-DM ...to coronary revascularization ... Voir le document complet

... ACS patients according to ESC guidelines were eligible [Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation ... Voir le document complet

... pseudonormalization, ST-segment depression, T-wave inversion, ST-segment elevation), cardiac marker status, heart rate, blood pressure, serum creatinine, creatinine clearance, Killip ... Voir le document complet

... 268 Patients and methods Patients Between January 1997 and May 1999, we prospectively analyzed 200 patients referred for coronary angioplasty for stable or Braunwald class IIa unstable ...more ... Voir le document complet

... This study has obvious limitations: firstly, it involved only one centre; secondly, it did not extend to assessing patient outcome; thirdly, the impact of the practice guidelines was assessed shortly after their ... Voir le document complet

... changed with the REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl– Intervention Trial), 114 which evaluated a high-dosage (ie, 4 g/d) treatment with icosapent ethyl, a stable ... Voir le document complet